Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 3
1997 3
1998 11
1999 6
2000 6
2001 6
2002 6
2003 6
2004 6
2005 14
2006 11
2007 10
2008 11
2009 10
2010 14
2011 12
2012 13
2013 16
2014 16
2015 10
2016 15
2017 17
2018 20
2019 23
2020 15
2021 14
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

280 results
Results by year
Filters applied: . Clear all
Page 1
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Fellström BC, et al. Among authors: de fijter jw. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. Lancet. 2017. PMID: 28363480 Clinical Trial.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM. Reinwald M, et al. Among authors: de fijter jw. Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16. Clin Microbiol Infect. 2018. PMID: 29454849 Free article. Review.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Berger SP, et al. Among authors: de fijter jw. Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1. Am J Transplant. 2019. PMID: 31152476 Free article. Clinical Trial.
Sirolimus and everolimus in kidney transplantation.
Moes DJ, Guchelaar HJ, de Fijter JW. Moes DJ, et al. Among authors: de fijter jw. Drug Discov Today. 2015 Oct;20(10):1243-9. doi: 10.1016/j.drudis.2015.05.006. Epub 2015 Jun 4. Drug Discov Today. 2015. PMID: 26050578 Review.
The authors reply.
Winne Bredewold O, De Fijter JW, Rabelink T. Winne Bredewold O, et al. Among authors: de fijter jw. Kidney Int. 2014 Mar;85(3):713-4. doi: 10.1038/ki.2013.480. Kidney Int. 2014. PMID: 24583995 Free article. No abstract available.
mTOR inhibitor-associated dermatologic and mucosal problems.
Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. Campistol JM, et al. Among authors: de fijter jw. Clin Transplant. 2010 Mar-Apr;24(2):149-56. doi: 10.1111/j.1399-0012.2010.01232.x. Epub 2010 Mar 4. Clin Transplant. 2010. PMID: 20236129 Review.
280 results